Ligand Pharmaceuticals (LGND) Total Non-Current Liabilities (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Total Non-Current Liabilities of $517.7 million for Q1 2026, down 1.73% sequentially from $526.8 million in Q4 2025, and up 441.19% YoY from $95.7 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Total Non-Current Liabilities for 17 years, with the latest figure at $517.7 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 441.19% year-over-year to $517.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $517.7 million (up 441.19% YoY) and the FY2025 annual result came in at $526.8 million, up 548.99% from the prior year.
- Total Non-Current Liabilities retreated to $517.7 million in Q1 2026 per LGND's latest filing, from $526.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $526.8 million in Q4 2025 and troughed at $57.7 million in Q3 2023.
- A 5-year average of $192.6 million and a median of $105.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities slumped 72.85% in 2023, then soared 548.99% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $137.4 million in 2022, then slumped by 57.4% to $58.5 million in 2023, then soared by 38.65% to $81.2 million in 2024, then jumped by 548.99% to $526.8 million in 2025, then slipped by 1.73% to $517.7 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $517.7 million, $526.8 million, and $506.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Bn |
| Mar 31, 2026 | 517.67 Mn |
| Dec 31, 2025 | 526.80 Mn |
| Sep 30, 2025 | 506.69 Mn |
| Jun 30, 2025 | 105.71 Mn |
| Mar 31, 2025 | 95.65 Mn |
| Dec 31, 2024 | 81.17 Mn |
| Sep 30, 2024 | 83.81 Mn |
| Jun 30, 2024 | 61.86 Mn |
| Mar 31, 2024 | 79.57 Mn |
| Dec 31, 2023 | 58.55 Mn |
| Sep 30, 2023 | 57.66 Mn |
| Jun 30, 2023 | 71.55 Mn |
| Mar 31, 2023 | 142.90 Mn |
| Dec 31, 2022 | 137.43 Mn |
| Sep 30, 2022 | 212.36 Mn |
| Jun 30, 2022 | 252.00 Mn |
| Mar 31, 2022 | 282.80 Mn |
| Dec 31, 2021 | 446.88 Mn |
| Sep 30, 2021 | 434.46 Mn |